Annual CFO
N/A
December 1, 2024
Summary
- ABBV annual cash flow from operations is not available.
Performance
ABBV Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly CFO
N/A
December 1, 2024
Summary
- ABBV quarterly cash flow from operations is not available.
Performance
ABBV Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM CFO
N/A
December 1, 2024
Summary
- ABBV TTM cash flow from operations is not available.
Performance
ABBV TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
ABBV Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | - | - | - |
| 5 y5 years | - | - | - |
ABBV Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time |
AbbVie Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $5.45 B(+139.9%) | $16.51 B(-11.4%) |
| Jun 2024 | - | $2.27 B(-43.8%) | $18.64 B(-17.8%) |
| Mar 2024 | - | $4.04 B(-15.0%) | $22.69 B(-0.7%) |
| Dec 2023 | $22.84 B(-8.4%) | $4.75 B(-37.2%) | $22.84 B(-10.5%) |
| Sep 2023 | - | $7.57 B(+19.9%) | $25.51 B(-0.1%) |
| Jun 2023 | - | $6.32 B(+50.7%) | $25.54 B(+5.4%) |
| Mar 2023 | - | $4.19 B(-43.6%) | $24.23 B(-2.9%) |
| Dec 2022 | $24.94 B(+9.5%) | $7.43 B(-2.3%) | $24.94 B(+10.4%) |
| Sep 2022 | - | $7.60 B(+51.9%) | $22.59 B(-1.5%) |
| Jun 2022 | - | $5.00 B(+2.0%) | $22.92 B(+0.5%) |
| Mar 2022 | - | $4.91 B(-3.3%) | $22.81 B(+0.1%) |
| Dec 2021 | $22.78 B(+29.5%) | $5.08 B(-36.0%) | $22.78 B(+1.0%) |
| Sep 2021 | - | $7.93 B(+62.3%) | $22.56 B(+10.3%) |
| Jun 2021 | - | $4.89 B(+0.3%) | $20.45 B(+9.7%) |
| Mar 2021 | - | $4.88 B(+0.5%) | $18.65 B(+6.0%) |
| Dec 2020 | $17.59 B(+32.0%) | $4.85 B(-16.7%) | $17.59 B(+9.9%) |
| Sep 2020 | - | $5.83 B(+88.7%) | $16.01 B(+8.7%) |
| Jun 2020 | - | $3.09 B(-19.0%) | $14.73 B(+4.3%) |
| Mar 2020 | - | $3.81 B(+16.5%) | $14.12 B(+6.0%) |
| Dec 2019 | $13.32 B(-0.8%) | $3.27 B(-28.1%) | $13.32 B(-0.9%) |
| Sep 2019 | - | $4.55 B(+83.9%) | $13.44 B(+0.2%) |
| Jun 2019 | - | $2.48 B(-17.9%) | $13.41 B(-2.8%) |
| Mar 2019 | - | $3.02 B(-11.1%) | $13.80 B(+2.8%) |
| Dec 2018 | $13.43 B(+34.8%) | $3.39 B(-25.0%) | $13.43 B(+6.4%) |
| Sep 2018 | - | $4.52 B(+57.9%) | $12.62 B(+11.0%) |
| Jun 2018 | - | $2.87 B(+8.4%) | $11.37 B(+8.2%) |
| Mar 2018 | - | $2.65 B(+2.4%) | $10.50 B(+5.5%) |
| Dec 2017 | $9.96 B | $2.58 B(-21.0%) | $9.96 B(+11.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2017 | - | $3.27 B(+63.3%) | $8.92 B(+25.6%) |
| Jun 2017 | - | $2.00 B(-4.7%) | $7.10 B(+1.2%) |
| Mar 2017 | - | $2.10 B(+36.4%) | $7.01 B(-0.4%) |
| Dec 2016 | $7.04 B(-6.6%) | $1.54 B(+6.0%) | $7.04 B(-5.7%) |
| Sep 2016 | - | $1.45 B(-24.2%) | $7.46 B(-8.6%) |
| Jun 2016 | - | $1.92 B(-9.9%) | $8.16 B(+1.1%) |
| Mar 2016 | - | $2.13 B(+8.4%) | $8.08 B(+7.2%) |
| Dec 2015 | $7.54 B(+112.3%) | $1.96 B(-8.9%) | $7.54 B(+50.9%) |
| Sep 2015 | - | $2.15 B(+17.6%) | $4.99 B(+8.0%) |
| Jun 2015 | - | $1.83 B(+15.6%) | $4.63 B(+2.5%) |
| Mar 2015 | - | $1.58 B(-374.2%) | $4.51 B(+27.1%) |
| Dec 2014 | $3.55 B(-43.4%) | -$578.00 M(-132.4%) | $3.55 B(-33.9%) |
| Sep 2014 | - | $1.79 B(+4.0%) | $5.37 B(-0.2%) |
| Jun 2014 | - | $1.72 B(+175.2%) | $5.38 B(-5.6%) |
| Mar 2014 | - | $624.00 M(-49.9%) | $5.70 B(-9.0%) |
| Dec 2013 | $6.27 B(-1.2%) | $1.25 B(-30.8%) | $6.27 B(+5.1%) |
| Sep 2013 | - | $1.80 B(-11.7%) | $5.96 B(-7.0%) |
| Jun 2013 | - | $2.04 B(+71.6%) | $6.41 B(+8.0%) |
| Mar 2013 | - | $1.19 B(+26.1%) | $5.94 B(-6.4%) |
| Dec 2012 | $6.34 B(+1.6%) | $941.00 M(-58.2%) | $6.34 B(-1.7%) |
| Sep 2012 | - | $2.25 B(+44.1%) | $6.45 B(+8.0%) |
| Jun 2012 | - | $1.56 B(-2.1%) | $5.97 B(-8.9%) |
| Mar 2012 | - | $1.59 B(+52.0%) | $6.56 B(+5.0%) |
| Dec 2011 | $6.25 B(+25.5%) | $1.05 B(-40.7%) | $6.25 B(+20.2%) |
| Sep 2011 | - | $1.77 B(-17.6%) | $5.20 B(+51.6%) |
| Jun 2011 | - | $2.15 B(+67.5%) | $3.43 B(+167.5%) |
| Mar 2011 | - | $1.28 B | $1.28 B |
| Dec 2010 | $4.98 B(-7.3%) | - | - |
| Dec 2009 | $5.37 B | - | - |
FAQ
- What is the all time high annual CFO for AbbVie?
- What is the all time high quarterly CFO for AbbVie?
- What is the all time high TTM CFO for AbbVie?
What is the all time high annual CFO for AbbVie?
AbbVie all-time high annual cash flow from operations is $24.94 B
What is the all time high quarterly CFO for AbbVie?
AbbVie all-time high quarterly cash flow from operations is $7.93 B
What is the all time high TTM CFO for AbbVie?
AbbVie all-time high TTM cash flow from operations is $25.54 B